AAUM (Average Assets Under Management) of ₹739.98 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 71.2% | 70.3% | ▼ -0.8% |
| Healthcare Services | 25.1% | 23.2% | ▼ -2.0% |
| Healthcare Equipment & Supplies | 0.6% | 4.7% | ▲ +4.1% |
| Chemicals & Petrochemicals | 1.8% | 1.5% | ▼ -0.3% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 70.3% | 69.0% | ▼ -1.4% |
| Healthcare Services | 23.2% | 21.1% | ▼ -2.1% |
| Healthcare Equipment & Supplies | 4.7% | 5.1% | ▲ +0.4% |
| Chemicals & Petrochemicals | 1.5% | 3.6% | ▲ +2.1% |
Comparing Aug 2026 → Sep 2026
| # | Stock | Sector | Weight (Sep 2026) |
|---|---|---|---|
| 1 | Prasol Chemicals Ltd. ₹18.48 Cr |
Chemicals & Petrochemicals | 2.24% |
| # | Stock | Sector | Last Weight (Aug 2026) |
|---|---|---|---|
| 1 | EQ - LAXMI DENTAL LIMITED ₹1.27 Cr |
Healthcare Equipment & Supplies | 0.17% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Molbio Diagnostics Ltd. ₹41.88 Cr |
Healthcare Equipment & Supplies | 4.53% | 5.08% | +0.55% |
| 2 | Laurus Labs Limited ₹23.76 Cr |
Pharmaceuticals & Biotechnology | 2.49% | 2.88% | +0.39% |
| 3 | Innova Captab Limited ₹11.60 Cr |
Pharmaceuticals & Biotechnology | 1.08% | 1.41% | +0.33% |
| 4 | Acutaas Chemicals Ltd ₹34.43 Cr |
Pharmaceuticals & Biotechnology | 3.91% | 4.17% | +0.26% |
| 5 | Krishna Institute Of Medical Sciences Limited ₹22.39 Cr |
Healthcare Services | 2.46% | 2.71% | +0.25% |
| 6 | Emcure Pharmaceuticals Limited ₹14.57 Cr |
Pharmaceuticals & Biotechnology | 1.57% | 1.77% | +0.20% |
| 7 | Aurobindo Pharma Limited ₹14.21 Cr |
Pharmaceuticals & Biotechnology | 1.57% | 1.72% | +0.15% |
| 8 | Gland Pharma Limited ₹26.09 Cr |
Pharmaceuticals & Biotechnology | 3.04% | 3.16% | +0.12% |
| 9 | Divi's Laboratories Limited ₹77.12 Cr |
Pharmaceuticals & Biotechnology | 9.25% | 9.35% | +0.10% |
| 10 | Jubilant Pharmova Limited ₹10.32 Cr |
Pharmaceuticals & Biotechnology | 1.15% | 1.25% | +0.10% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited ₹109.00 Cr |
Pharmaceuticals & Biotechnology | 13.96% | 13.21% | -0.75% |
| 2 | Max Healthcare Institute Limited ₹29.75 Cr |
Healthcare Services | 4.34% | 3.61% | -0.73% |
| 3 | Fortis Healthcare Limited ₹19.25 Cr |
Healthcare Services | 2.95% | 2.33% | -0.62% |
| 4 | Cipla Limited ₹26.92 Cr |
Pharmaceuticals & Biotechnology | 3.67% | 3.26% | -0.41% |
| 5 | Rubicon Research Limited ₹16.19 Cr |
Pharmaceuticals & Biotechnology | 2.37% | 1.96% | -0.41% |
| 6 | Sequent Scientific Limited ₹14.15 Cr |
Pharmaceuticals & Biotechnology | 2.01% | 1.71% | -0.30% |
| 7 | Apollo Hospitals Enterprise Limited ₹24.50 Cr |
Healthcare Services | 3.25% | 2.97% | -0.28% |
| 8 | Pfizer Limited ₹7.36 Cr |
Pharmaceuticals & Biotechnology | 1.16% | 0.89% | -0.27% |
| 9 | Park Medi World Limited ₹26.12 Cr |
Healthcare Services | 3.36% | 3.17% | -0.19% |
| 10 | Rainbow Childrens Medicare Limited ₹9.20 Cr |
Healthcare Services | 1.29% | 1.11% | -0.18% |
35 stocks — Sep 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹109.00 Cr |
Pharmaceuticals & Biotechnology |
13.21%
|
|
| 2 |
₹77.12 Cr |
Pharmaceuticals & Biotechnology |
9.35%
|
|
| 3 |
₹41.88 Cr |
Healthcare Equipment & Supplies |
5.08%
|
|
| 4 |
₹38.40 Cr |
Pharmaceuticals & Biotechnology |
4.65%
|
|
| 5 |
₹34.43 Cr |
Pharmaceuticals & Biotechnology |
4.17%
|
|
| 6 |
₹29.75 Cr |
Healthcare Services |
3.61%
|
|
| 7 |
₹26.92 Cr |
Pharmaceuticals & Biotechnology |
3.26%
|
|
| 8 |
₹26.12 Cr |
Healthcare Services |
3.17%
|
|
| 9 |
₹26.09 Cr |
Pharmaceuticals & Biotechnology |
3.16%
|
|
| 10 |
₹25.71 Cr |
Healthcare Services |
3.12%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.